{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T01:30:46Z","timestamp":1768527046726,"version":"3.49.0"},"reference-count":32,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2022]]},"abstract":"<b><i>Background:<\/i><\/b> Targeted therapy is used to treat patients with a BRAF-mutated metastatic melanoma and is continued until disease progression or severe toxicity. No robust data on the management of patients achieving a complete remission (CR) are available. <b><i>Main Objective:<\/i><\/b> To determine the relapse rate in the first year after targeted therapy discontinuation in patients in CR. <b><i>Secondary Objectives:<\/i><\/b> To determine the relapse rates throughout the follow-up and to identify prognostic factors for relapse at 1 year. <b><i>Methods:<\/i><\/b> A retrospective, monocentric observational study was conducted in patients with advanced melanoma included in the RIC-Mel database who discontinued targeted therapy after achieving a CR confirmed by CT scan and PET\/CT scan. <b><i>Results:<\/i><\/b> Twenty-nine patients were included. Seventeen (58.6%) patients were treated with BRAF inhibitor (BRAFi) alone and 12 (41.4%) with a BRAFi combined with a MEK inhibitor (BRAFi + MEKi). The median treatment duration was 9.7 months. The relapse rates after discontinuation were 69% at 12 months (BRAFi: 70.6%; BRAFi + MEKi: 66.7%) and 76% at 36 months (BRAFi: 76.5%; BRAFi + MEKi: 75%). A non-significant trend towards a higher risk of relapse was found in women (<i>p<\/i> = 0.1; RR 3.36; 95% CI 0.77\u201317.07), in patients with an LDH level greater than the upper limits of normal (<i>p<\/i> = 0.58; RR 2.43; 95% CI 0.10\u201356.71), and when more than two metastatic sites were involved (<i>p<\/i> = 0.19; RR 4.6; 95% CI 0.46\u201346.51). After relapse, targeted therapy was resumed in 17 patients (7 with BRAFi; 10 with BRAFi + MEKi) with a response rate of 53%. <b><i>Conclusions:<\/i><\/b> This real-life study provided long-term data in patients who discontinued targeted therapy after CR. Most patients experienced a relapse in the first year after targeted therapy discontinuation, of whom 50% were in the first 3 months. After targeted therapy resumption, 53% of relapsing patients achieved an objective response. Patients should be followed during the first year after treatment discontinuation. In addition, patients with less than 3 metastatic sites, a baseline LDH level with normal ranges, men, and patients responding rapidly to treatment would be more likely to maintain a CR after treatment discontinuation. <\/jats:p>","DOI":"10.1159\/000518718","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T21:02:29Z","timestamp":1651525349000},"page":"517-526","source":"Crossref","is-referenced-by-count":6,"title":["Should Targeted Therapy Be Continued in BRAF-Mutant Melanoma Patients after Complete Remission?"],"prefix":"10.1159","volume":"238","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7926-947X","authenticated-orcid":false,"given":"Eve","family":"B\u00e9douelle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Michel","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Varey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Khammari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Dreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.04.030"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041245"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.07.027"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30388-2"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904059"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60868-X"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408868"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2217\/mmt.15.22"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1412690"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60898-4"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.1025"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30142-6"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00198"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.05.033"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000169"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000350"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15345"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.321"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75837-5"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30578-2"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.9345"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx176"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000948"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4799"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014548187"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1060-8"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30934-X"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0448-9"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001806"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1082-2"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/518718","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/518718","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:18:47Z","timestamp":1745421527000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000518718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,5,2]]},"published-print":{"date-parts":[[2022,5,10]]}},"URL":"https:\/\/doi.org\/10.1159\/000518718","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]}}}